secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001213900-25-050913
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding
--------------------------------------------------------------------------------

- SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
- Cash & equivalents $5.7M as of April 30, 2025; Q1 2025 net loss $1.9M, FY2024 net loss $7.7M.
- April 2025 private placement raised $3.8M gross; company aims to raise at least $30M total through FY2027.
- Workforce reduced to 5 employees after CTO departure; cost-saving measures implemented.
- Annual meeting June 18, 2025: board to shrink from 6 to 5, reverse stock split proposals to maintain Nasdaq listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025050913/0001213900-25-050913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025050913/ea0244646-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer